JPMorgan analyst Anupam Rama raised the firm’s price target on Nuvalent to $90 from $87 and keeps an Overweight rating on the shares. The firm updated models in smid-cap biotechnology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL: